# EDGAR Filing Document

**Accession Number:** 0000858581
**File Stem:** 0001193125-23-045954
**Filing Date:** 2023-2
**Character Count:** 147362
**Document Hash:** e7a37550a14732b434bef24af255955f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-045954.hdr.sgml**: 20230223

**ACCESSION NUMBER**: 0001193125-23-045954

**CONFORMED SUBMISSION TYPE**: N-CSR

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20221231

**FILED AS OF DATE**: 20230223

**DATE AS OF CHANGE**: 20230223

**EFFECTIVENESS DATE**: 20230223

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** T. Rowe Price Index Trust, Inc.
- **CENTRAL INDEX KEY:** 0000858581
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** MD
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** N-CSR
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-05986
- **FILM NUMBER:** 23657658

**BUSINESS ADDRESS:**
- **STREET 1:** 100 EAST PRATT STREET
- **CITY:** BALTIMORE
- **STATE:** MD
- **ZIP:** 21202
- **BUSINESS PHONE:** 410-345-2000

**MAIL ADDRESS:**
- **STREET 1:** 100 EAST PRATT STREET
- **CITY:** BALTIMORE
- **STATE:** MD
- **ZIP:** 21202

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PRICE T ROWE INDEX TRUST INC
- **DATE OF NAME CHANGE:** 19920703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PRICE T ROWE INSTITUTIONAL EQUITY FUNDS INC
- **DATE OF NAME CHANGE:** 19900227

## Series and Classes Contracts Data

### T. Rowe Price Mid-Cap Index Fund (Series ID: S000051326)

| Class ID   | Class Name                               | Ticker Symbol   |
|:---|:---|:---|
| C000161835 | T. Rowe Price Mid-Cap Index Fund         |  |
| C000161836 | T. Rowe Price Mid-Cap Index Fund-I Class |  |
| C000219328 | T. Rowe Price Mid-Cap Index Fund-Z Class | TRSZX           |

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

# **FORM N-CSR**

# **CERTIFIED SHAREHOLDER REPORT OF REGISTERED
MANAGEMENT INVESTMENT COMPANIES**

Investment Company Act File Number: 811-05986

T. Rowe Price Index Trust, Inc.

(Exact name of registrant as specified in charter)

100 East Pratt Street, Baltimore, MD 21202

(Address of principal executive offices)

David Oestreicher

100 East Pratt Street, Baltimore, MD 21202

(Name and address of agent for service)

Registrant's telephone number, including area code: (410) 345-2000

Date of fiscal year end: December 31

Date of reporting period: December 31, 2022

# ---**Item 1. Reports to Shareholders**

# **(a) Report pursuant to Rule 30e-1**

T.RowePrice®

# **ANNUAL REPORT**

December 31, 2022

| TRMNX | T. ROWE PRICE Mid-Cap Index Fund |
| --- | --- |
| TRMSX | Mid-Cap Index Fund- I Class |

INVEST WITH CONFIDENCE®

Mid-cap U.S. stocks plunged as Russia's assault on Ukraine, surging commodity prices, elevated inflation, and rising interest rates weighed heavily on the economy and the financial markets during the 12-month period. The Mid-Cap Index Fund slightly underperformed its benchmark, the Russell Select Midcap Index.

Sector performance within the Russell index was mostly negative during the period. The information technology was used for the highest detractor and

Z Class

## Go Paperless

Sign up for e-delivery of your statements, confirmations, and prospectuses or shareholder reports.

### TO ENROLL:

If you invest directly with T. Rowe Price, go to **troweprice.com/paperless**.

If you invest through an investment advisor, a bank, or a brokerage firm, please contact that organization and ask if it can provide electronic documentation.

**It's fast**-receive your statements and confirmations faster than U.S. mail.

**It's convenient**-access your important account documents whenever you need them.

**It's secure**-we protect your online accounts using 'True Identity' to confirm new accounts and make verification faster and more secure.

**It can save you money**-where applicable, T. Rowe Price passes on the cost savings to fund holders.*

* Certain mutual fund accounts that are assessed an annual account service fee can also save money by switching to e-delivery.

T. ROWE PRICE MID-CAP INDEX FUND

Market Commentary

# **HIGHLIGHTS**

displayed double-digit losses, while the energy sector exhibited very mild gains.

The fund employs a full replication strategy which involves investing substantially all of its assets in all of the stocks in the index and seeking to maintain holdings of each stock in proportion to its weight in the index. As of December 31, 2022, information technology was the fund's largest sector allocation. The portfolio had very little exposure to the utilities and consumer staples sectors.

Log in to your account at troweprice.com for more information.

T. ROWE PRICE MID-CAP INDEX FUND

## Dear Shareholder

The trade interest of the company is a detailed and unbiased investment in the market. The market is a significant market for the market. The market is a significant market for the market. The market is a significant market for the market. The market is a significant market for the market. The market is a significant market for the market. The market is a significant market for the market. The market is a significant market for the market. The market is a significant market for the market. The market is a significant market for the market. The market is a significant market for the market. The market is a significant market for the market.

1

T. ROWE PRICE MID-CAP INDEX FUND

Management's Discussion of Fund Performance

sharp increase in yields led to historically weak results across the fixed income
with the S&P 500 Index, energy was a rare bright spot, gaining more than

60% as oil prices jumped in response to Russia's invasion of Ukraine and
the past year has been a strong, low- and low-impact, as low- and low-impact
concerns over commodity supply shortages. Defensive shares, such as utilities,
unshocked by the broad headwinds that markets faced and volatility may
consumer staples, and health care, held up relatively well and finished the
continue in the near term as central banks tighten policy amid slowing
year with roughly flat returns. Conversely, communication services, consumer
economic growth. However, in our view, there continue to be opportunities for
discretionary and information technology shares suffered the largest declines.
Investments focused on fundamentals. Valuations in most global equity
investment professionals go to

troweprice.com

| Periods Ended 12/31/22 | Total Return |  |
| --- | --- | --- |
|  | 6 Months | 12 Months |
| Mid-Cap Index Fund | 1.32% | -28.63% |
| Mid-Cap Index Fund- I Class | 1.31 | -28.57 |

2

T. ROWE PRICE MID-CAP INDEX FUND

# **INVESTMENT OBJECTIVE**

period, although there were some time since the investment was a major issue for year. The Mid-Cap Index Fund received 28,000 shares of 2015, and was benchmarked, most November's investments the 2018-2019 financial baseline inflation rising the Russia's 5,000-midcap index Fund performance and a 7.1% on a 12-month basis, the lowest level since December 2021 but still well. The 7,000-midcap index Fund was a major issue for the 2018-2019 financial baseline inflation in the first 7,000-midcap index Fund. The 7,000-midcap index Fund was a major issue for the 2018-2019 financial baseline inflation in the first 7,000-midcap index Fund. The 7,000-midcap index Fund was a major issue for the 2018-2019 financial baseline inflation in the first 7,000-midcap index Fund.

| Mid-Cap Index Fund- |  |  |
| --- | --- | --- |
| Z Class | 1.37 | -28.47 |
| Russell Select Midcap |  |  |
| Index | 1.39 | -28.50 |

3

T. ROWE PRICE MID-CAP INDEX FUND

The consumer discretionary sector also exhibited negative returns, as the

|  | Percent of Net Assets |  |
| --- | --- | --- |
|  | 6/30/22 | 12/31/22 |
| Information Technology | 24.6% | 22.5% |
| Industrials and Business Services | 13.8 | 15.4 |

4

T. ROWE PRICE MID-CAP INDEX FUND

At the end of our reporting

Financials 149 151
Consumer 148 150
Health Care 148 152
Real Estate 147 156
Materials 147 160
Communications 145 160
Energy 144 160

5

T. ROWE PRICE MID-CAP INDEX FUND

# RISKS OF INVESTING IN THE MID-CAP INDEX FUND

or industry
Consumer Dispute
Utilities
Other and Reserve
Total
Historical
classifications

6

T. ROWE PRICE MID-CAP INDEX FUND

**BENCHMARK INFORMATION**

~~purchasies, new, more, different, and more, in the portfolio.~~

**TWENTY-FIVE LARGEST HOLDINGS**

Percent of
Net Assets
12/31/22

7

T. ROWE PRICE MID-CAP INDEX FUND

Blackstone
Uber Technology
Snowflake
Palo Alto
Cheniere
Lululemon
Block

The purpose of each stock in proportion to its weight in the index. Since 1.4
the portfolio is designed to track its index, it does not have the flexibility to
the return of the fund. We expected to be slightly below the return of the 1.3
the impact of the fund on the market. The impact of the fund on the market is based on the
the impact of the fund on the market. The impact of the fund on the market is based on the
the impact of the fund on the market. The impact of the fund on the market is based on the
the impact of the fund on the market. The impact of the fund on the market is based on the
the impact of the fund on the market. The impact of the fund on the market is based on the
the impact of the fund on the market.

![img-0.jpeg](img-0.jpeg)

As of 12/31/22

| Mid-Cap Index Fund | $18,169 |
| --- | --- |
| Russell Select Midcap Index | 18,410 |

8

T. ROWE PRICE MID-CAP INDEX FUND

# **GROWTH OF \$10,000**

Airbnb cap stocks and to attempt to track the index's performance.

0.9

|  | Periods Ended 12/31/22 | 1 Year | 5 Years | Since Inception | Inception Date |
| --- | --- | --- | --- | --- | --- |
| The views change is a forecast | Mid-Cap Index Fund | -28.63% | 5.81% | 8.83% | 12/9/15 |
|  | Mid-Cap Index Fund- I Class | -28.57 | 5.92 | 8.94 | 12/9/15 |

$2

9

T. ROWE PRICE MID-CAP INDEX FUND

| AVERAGE | ANNUAL | COMPOUND | TOTAL | RETURN |  |
| --- | --- | --- | --- | --- | --- |
| Mid-Cap Index Fund- Z Class |  |  | -28.47 | 20.22 |  |
| Veeva Systems |  |  |  | 3/16/20 |  |
| Comptroller, Healthcare |  |  |  | 0.7 |  |
| Household and the fund has three share classes. The Investor Class charges for418,000,000 |  |  |  |  |  |
| Investigation of how much Current performance may be lower or higher than the |  |  |  |  |  |
| Taxes of 12B-1, the 1 Class shares are also available to institutionally oriented clients and |  |  |  |  |  |
| taxed at 12B-1 or administrative fee payment. The 2 Class shares are offered only to the |  |  |  |  |  |
| taxed at 12B-1 or administrative fee payment. The 2 Class shares are offered only to the |  |  |  |  |  |
| taxed at 12B-1 or administrative fee payment. The 2 Class shares are offered only to the |  |  |  |  |  |
| Taxed at 12B-1 or administrative fee payment. The 2 Class shares are offered only to the |  |  |  |  |  |
| Taxed at 12B-1 or administrative fee payment. The 2 Class shares are offered only to the |  |  |  |  |  |

10

T. ROWE PRICE MID-CAP INDEX FUND

# **FUND EXPENSE EXAMPLE (CONTINUED)**

| a constant rate. Average annual total return figures include 0.5 |  |  |  |
| --- | --- | --- | --- |
| MID-CAP INDEX FUND |  |  |  |
|  | Beginning Account Value | Ending Account Value | Expenses Paid During Period* |
|  | 7/1/22 | 12/31/22 | 7/1/22 to 12/31/22 |
| Investor Class |  |  |  |
| EXPENSE Actual | $1,000.00 | $1,013.20 | $1.37 |

11

T. ROWE PRICE MID-CAP INDEX FUND

The information on the second line of the table (Hypothetical) is based on hypothetical account values and expenses derived from the fund's actual expenses and an assumed 5% net interest return before expenses (not the fund's actual return). You may compare the ongoing costs of investing in the fund with other funds by contrasting this 5% hypothetical example. The notes that appear in the shareholder reports of the other funds and expenses may not be used to estimate the actual ending value of the period.

| NET ASSET VALUE | $19.55 | $18.37 | $13.47 | $11.00 | $12.77 |
| --- | --- | --- | --- | --- | --- |
| Beginning of period |  |  |  |  |  |
| Investment activities |  |  |  |  |  |
| Net investment income (1)(2) | 0.16 | 0.13 | 0.11 | 0.14 | 0.18 |

12

T. ROWE PRICE MID-CAP INDEX FUND

**FINANCIAL INFORMATION** The above elsewhere in this report because it is based on a different time and time of the financial year. The financial year is changed to a quarterly basis, but the last week of the financial year is changed to a quarterly basis. The financial year is changed to a quarterly basis. The financial year is changed to a quarterly basis.

|  | $ | $ | $ | $ | $ |
| --- | --- | --- | --- | --- | --- |
| I Class |  |  |  |  |  |
| FL |  |  |  |  |  |
| Net investment income | $(0.16) | $(0.11) | $(0.11) | $(0.16) | $(0.17) |
| Beginning of period | (0.11) | (0.66) | (0.53) | (0.60) | (0.59) |
| Net realized gain | (0.25) | (0.77) | (0.64) | (0.76) | (0.76) |
| Total distributions |  |  |  |  |  |
| Investment activities |  |  |  |  |  |
| Net investment income (1)(2) | 0.18 | 0.18 | 0.12 | 0.16 | 0.19 |

13

T. ROWE PRICE MID-CAP INDEX FUND

| FINANCIAL IMPORVEMENTS |  | Completing the liabilities of this fund with other funds. |  |
| --- | --- | --- | --- |
| Funds and other fund expenses |  | The following example is intended to help you understand the following conditions of the fund: |  |
| You understand, put, and use the basis of the following conditions of the fund: |  |  |  |
| costs with the remaining costs of investing in the fund and the funds in the fund are based on an investment of $5,000 in the first half of the year. |  |  |  |
| The amount of $5,000 invested in the fund is based on the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount of the amount |  |  |  |
| NZ Class |  | different funds. To the extent a fund |  |
| E |  | 19.00 | $15.00 |
|  |  | 1.00 | $1.00 |
|  |  | 12/31/22 | 12/31/21 |
| Distributions |  |  |  |
| Funds and other fund |  |  |  |
| Total investment income |  | (0.16) | (0.13) |
| Beginning of period |  | (0.11) | (0.66) |
| Net realized gain |  | (0.11) | (0.66) |
| Total return |  | (28.53)% | (15.69)% |
| Investment activities |  | (0.27) | (0.79) |
| Net investment income (2)(3) |  |  |  |
|  |  | 0.21 | 0.22 |
|  |  |  | 0.11 |

14

T. ROWE PRICE MID-CAP INDEX FUND

December 31, 2022

# FINANCIAL HIGHLIGHTS

|  | Shares | $ Value |  |
| --- | --- | --- | --- |
| (Cost and value in $000s) |  |  |  |
| COMMON STOCKS - 99.9% |  |  |  |
| NET ASSET VALUE (estimated gain/loss) | (5.77) | 1.79 |  |
| End of year-end balance (current) |  |  |  |
| End of year-end balance (current) |  |  |  |
| COMMONIZATION SERVICES 4.3% | $13.75 | $19.60 |  |
|  | $16.48 | $13.40 |  |
|  | $3.14% | $3.21% |  |
|  |  | $18.00 |  |
| Deferred Telecommunication Services 0.2% |  |  |  |
| Payments by Price Associates | 0.27% | 0.30% | 0.21% |
| Net Assets (current) |  |  | 0.30% |
| Net Assets (current) |  |  | 0.25% |
| Rate of Sale (current) |  |  | 0.25% |
| Total distributions | 1.00% | 0.69% | 0.75% |
| Total return rate | (28.57)% | 10.77% | 41.45% |
|  |  |  | 29.59% |
|  |  |  | (8.17)% |

Net assets end of period (in

15

T. ROWE PRICE MID-CAP INDEX FUND

# **CRITICALS OF INVESTMENTS**[{"box_2d": [35, 93, 617, 231], "label": "table", "caption": "

|  | Shares | US$ Value |  |
| --- | --- | --- | --- |
| Entertainment 1.5% (cost and value in $000s) |  |  |  |
| AMC Entertainment Holdings, Class A (1)(2) | 14,040 | 57 |  |
| Automobiles 0.3% |  |  |  |
| End of period: 1.5% | $237 | $8,724 | $5,270 |
| Liability: 1.5% | $13.75 | $18.40 | $18.41 |
| Liability: 1.5% |  | $18.40 | $18.41 |
| Liability: 1.5% |  | $18.40 | $18.41 |
| Liability: 1.5% |  | $18.40 | $18.41 |
| Liability: 1.5% |  | $18.40 | $18.41 |
| Liability: 1.5% |  | $18.40 | $18.41 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |
| Liability: 1.5% | $13.75 | $18.40 |
| Liability: 1.5% |  | $18.40 |
| Liability: 1.5% |  | $18.40 |
| Liability: 1.5% |  | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |
| Liability: 1.5% | $13.75 | $18.40 |
| Liability: 1.5% |  | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |
| Liability: 1.5% | $13.75 | $18.40 |
| Liability: 1.5% |  | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |
| Liability: 1.5% | $13.75 | $18.40 |
| Liability: 1.5% |  | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |
| Liability: 1.5% | $13.75 | $18.40 |
| Liability: 1.5% |  | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |
| Liability: 1.5% | $13.75 | $18.40 |
| Liability: 1.5% |  | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |
| Liability: 1.5% | $13.75 | $18.40 |
| Liability: 1.5% |  | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |
| Liability: 1.5% | $13.75 | $18.40 |
| Liability: 1.5% |  | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |
| Liability: 1.5% | $13.75 | $18.40 |
| Liability: 1.5% |  | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |
| Liability: 1.5% | $13.75 | $18.40 |
| Liability: 1.5% |  | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |
| Liability: 1.5% | $13.75 | $18.40 |

|  | Shares | US$ Value |
| --- | --- | --- |

<tr><td>Liability: 1.5%</td><td>$13.75</td><td>$18.40</td></tr></table>

|  | Shares | US$ Value |
| --- | --- | --- |

<tr><td>Liability: 1.5%</td><td>$13.75</td><td>$18.40</td></tr></table>

|  | Shares | US$ Value |
| --- | --- | --- |

<tr><td>Liability: 1.5%</td><td>$13.75</td><td>$18.40</td></tr></table>

|  | Shares | US$ Value |
| --- | --- | --- |

<tr><td>Liability: 1.5%</td><td>$13.75</td><td>$18.40</td></tr></table>

|  | Shares | US$ Value |
| --- | --- | --- |

<tr><td>Liability: 1.5%</td><td>$13.75</td><td>$18.40</td></tr></tabletabletable><thead><tr><th></th><th>Shares</th><th>US$ Value</th></tr></table><tr><td>Liability: 1.5%</td><td>$13.75</td><td>$18.40</td></tr></tabletabletable><thead><tr><th></th><th>Shares</th><th>US$ Value</th></tr></table><tr><td>Liability: 1.5%</td><td>$13.75</td><td>$18.40</td></tr></tabletabletable><thead><tr><th></th><th>Shares</th><th>US$ Value</th></tr></table><tr><td>Liability: 1.5%</td><td>$13.75</td><td>$18.40</td></tr></tabletabletable><thead><tr><th></th><th>Shares</th><th>US$ Value</th></tr></table><tr><td>Liability: 1.5%</td><td>$13.75</td><td>$18.40</td></tr></table

16

T. ROWE PRICE MID-CAP INDEX FUND

| ROBLOX, Class A (1) | 12,045 | 343 |
| --- | --- | --- |
| Roku (1) | 3,273 | 911 |
| Diversified Consumer Services 0.8% | 3,769 | 297 |
| (1.0% and value in $000s) |  |  |
| AGM42 Wrestling Entertainment, Class A | 5,185 | 80 |
| Sales/Discounted Earnings, 1.0% and 1.0% | $460 | $2,460 |
| Sales/Discounted Earnings, 1.0% and 1.0% | 15,437 | 2,437 |
| Sales/Discounted Earnings, 1.0% and 1.0% | 0.40% | 3.07% |
| Net Income, 1.0% and 1.0% | 0.00% | 0.00% |
| Net Income, 1.0% and 1.0% | 0.00% | 0.00% |
| Net Income, 1.0% and 1.0% | 1.32% | 1.00% |
| Net Income, 1.0% and 1.0% | 2.25% | 1.00% |
| Net Income, 1.0% and 1.0% | 2.25% | 1.00% |
| Net Income, 1.0% and 1.0% | 2.25% | 1.00% |
| Net Income, 1.0% and 1.0% | 2.25% | 1.00% |

17

T. ROWE PRICE MID-CAP INDEX FUND

| Service Corp. International | 4,026 | 279 |
| --- | --- | --- |
| Maritime Retail 0.4% | 2,757 | 20 |
| ZoomInfo Technologies (1) | Shares | $ Value |
| Models, Restaurants & Leisure 3.1% | 3,147 | 79 |
| MacOS | 7,245 | 164 |
| Multi-Store A (1) | 10,111 | 864 |
| Multi-Store STAPLES 2.8% | 2,855 | 20 |
| Multi-Store B | 6,242 | 256 |
| Multi-Store C | 2,856 | 19 |
| Multi-Store D | 2,162 | 117 |
| Multi-Store E | 1,162 | 117 |
| Multi-Store F | 1,162 | 117 |
| Multi-Store G | 1,162 | 117 |
| Multi-Store H | 1,162 | 117 |
| Multi-Store I | 1,162 | 117 |
| Multi-Store J | 1,162 | 117 |
| Multi-Store K | 1,162 | 117 |
| Multi-Store L | 1,162 | 117 |
| Multi-Store M | 1,162 | 117 |
| Multi-Store N | 1,162 | 117 |
| Multi-Store O | 1,162 | 117 |
| Multi-Store P | 1,162 | 117 |
| Multi-Store Q | 1,162 | 117 |
| Multi-Store R | 1,162 | 117 |
| Multi-Store S | 1,162 | 117 |
| Multi-Store T | 1,162 | 117 |
| Multi-Store U | 1,162 | 117 |
| Multi-Store V | 1,162 | 117 |
| Multi-Store W | 1,162 | 117 |
| Multi-Store X | 1,162 | 117 |
| Multi-Store Y | 1,162 | 117 |
| Multi-Store Z | 1,162 | 117 |
| Multi-Store AA | 1,162 | 117 |
| Multi-Store AB | 1,162 | 117 |
| Multi-Store AC | 1,162 | 117 |
| Multi-Store AD | 1,162 | 117 |
| Multi-Store AE | 1,162 | 117 |
| Multi-Store AF | 1,162 | 117 |
| Multi-Store AG | 1,162 | 117 |
| Multi-Store AH | 1,162 | 117 |
| Multi-Store AI | 1,162 | 117 |
| Multi-Store AJ | 1,162 | 117 |
| Multi-Store AK | 1,162 | 117 |
| Multi-Store AL | 1,162 | 117 |
| Multi-Store AM | 1,162 | 117 |
| Multi-Store AN | 1,162 | 117 |
| Multi-Store AO | 1,162 | 117 |
| Multi-Store AP | 1,162 | 117 |
| Multi-Store AQ | 1,162 | 117 |
| Multi-Store AR | 1,162 | 117 |
| Multi-Store AS | 1,162 | 117 |
| Multi-Store AT | 1,162 | 117 |
| Multi-Store AU | 1,162 | 117 |
| Multi-Store AV | 1,162 | 117 |
| Multi-Store AW | 1,162 | 117 |
| Multi-Store AX | 1,162 | 117 |
| Multi-Store AY | 1,162 | 117 |
| Multi-Store AZ | 1,162 | 117 |
| Multi-Store BA | 1,162 | 117 |
| Multi-Store BB | 1,162 | 117 |
| Multi-Store BC | 1,162 | 117 |
| Multi-Store CD | 1,162 | 117 |
| Multi-Store CE | 1,162 | 117 |
| Multi-Store CF | 1,162 | 117 |
| Multi-Store CG | 1,162 | 117 |
| Multi-Store CH | 1,162 | 117 |
| Multi-Store DI | 1,162 | 117 |
| Multi-Store DJ | 1,162 | 117 |
| Multi-Store DK | 1,162 | 117 |
| Multi-Store DL | 1,162 | 117 |
| Multi-Store DM | 1,162 | 117 |
| Multi-Store DN | 1,162 | 117 |
| Multi-Store DO | 1,162 | 117 |
| Multi-Store DP | 1,162 | 117 |
| Multi-Store DQ | 1,162 | 117 |
| Multi-Store DR | 1,162 | 117 |
| Multi-Store DS | 1,162 | 117 |
| Multi-Store DT | 1,162 | 117 |
| Multi-Store DU | 1,162 | 117 |
| Multi-Store DV | 1,162 | 117 |
| Multi-Store DW | 1,162 | 117 |
| Multi-Store DX | 1,162 | 117 |
| Multi-Store DY | 1,162 | 117 |
| Multi-Store DX | 1,162 | 117 |
| Multi-Store DY | 1,162 | 117 |
| Multi-Store DY | 1,162 | 117 |
| Multi-Store DY | 1,162 | 117 |
| Multi-Store DY | 1,162 | 117 |

(a) Annualized

18

T. ROWE PRICE MID-CAP INDEX FUND

| Food & Staples Retaining 1.2% | 9,482 | 100 |
| --- | --- | --- |
| Drinking Water, Group, SinusXM, Class A (1) | 2,000 | 5 Value |
| Drinking Water, Group, SinusXM, Class C (1) | 2,000 | 5 Value |
| Drinking Water, Group, SinusXM, Class (1) | 2,000 | 5 Value |
| Drinking Water, Group, SinusXM, Class (1) | 2,000 | 5 Value |
| Drinking Water, Group, SinusXM, Class (1) | 2,000 | 5 Value |
| Drinking Water, Group, SinusXM, Class A | 2,000 | 5 Value |
| Drinking Water, Group, SinusXM, Class A (1) | 2,000 | 5 Value |
| Drinking Water, Group, SinusXM, Class A (1) | 2,000 | 5 Value |
| Drinking Water, Group, SinusXM, Class A (1) | 2,000 | 5 Value |
| Drinking Water, Group, SinusXM, Class A (1) | 2,000 | 5 Value |

The following table provides the original part of these financial statements:

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves

Change Reserves[{"box_2d": [30, 175, 619, 189], "label": "text", "[{"box_2d": [30, 175, 619, 189], "label": "text", "[{"box_2d": [30, 175, 619, 189], "label": "text", "[{"box_2d": [30, 175, 619, 189], "label": "text", " [ 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310,

T. ROWE PRICE MID-CAP INDEX FUND

| Total Stockholders' Services | 4,387 | 3,903 |
| --- | --- | --- |
| CONSUMER DISCRETIONARY 11.6% | 3,785 | 3,106 |
| Annual Liabilities | 3,785 | 3,106 |
| Accumulated Liabilities | 705 | 705 |
| Accumulated Liabilities (1)(2) | 4,308 | 3,890 |
| Accumulated Liabilities (1)(2) | 4,308 | 3,890 |
| Net Interest | 2,112 | 2,112 |
| Net Interest | 9,612 | 3,483 |
| Liabilities | 2,112 | 2,112 |
| Liabilities (1)(2) | 2,112 | 2,112 |
| Liabilities (1)(2) | 2,112 | 2,112 |
| Liabilities (1)(2) | 2,112 | 2,112 |
| Liabilities (1)(2) | 2,112 | 2,112 |

20

T. ROWE PRICE MID-CAP INDEX FUND

| Textiles: Apparel & Luxury Goods 2.2% | 3,000 | 100 |
| --- | --- | --- |
| Data: Apparel, Class A | 2,000 | 5,000 |
| Internet & Direct Marketing Retail 0.4% | 2,000 | 5,000 |
| Business Products 0.1% | 3,000 | 4,000 |
| Business Products 0.7% | 5,000 | 7,000 |
| Business Products Investment Trusts 0.7% | 5,000 | 7,000 |
| Business Products | 5,000 | 7,000 |
| Business Products, Class A | 5,000 | 7,000 |
| Business Products, REIT | 5,000 | 7,000 |
| Business Products 0.1% | 14,000 | 20,000 |
| Business Products | 6,000 | 11,000 |
| Starwood Property Trust, REIT | 7,000 | 14,000 |

21

T. ROWE PRICE MID-CAP INDEX FUND

| Business-USA Class A (1) | 8,859 | 184 |
| --- | --- | --- |
| Business-USA Class A (1) | 2,111 | 104 |
| Business-USA Class A (1) | 3,000 | 5 Value |
| Business-USA Class A (1) | 6,000 | 140 |
| Business-USA Class A (1) | 7,925 | 200 |
| Business-USA Class A (1) | 17,874 | 2,000 |
| Business-USA Class A (1) | 13,000 | 10,000 |
| Business-USA Class A (1) | 5,000 | 100 |
| Business-USA Class A (1) | 10,000 | 200 |
| Business-USA Class A (1) | 2,000 | 100 |
| Business-USA Class A (1) | 10,000 | 200 |
| Business-USA Class A (1) | 2,000 | 100 |
| Business-USA Class A (1) | 10,000 | 200 |

22

T. ROWE PRICE MID-CAP INDEX FUND

| Voya Financial | 2,614 | MA |
| --- | --- | --- |
| Amended Financial | 1,800 | 100 |
| Dividends & Consumable Fuels 3.6% | Shares | 1.5 Value |
| Interest | 362 | 3,000 |
| Interest on Assets (1.5%) | 9,000 | 100 |
| Capital Markets 5.4% | 1,000 | 100 |
| Dividends on Assets | 1,000 | 100 |
| Amended Financial Group | 1,000 | 100 |
| Amended Financial Group (1) | 1,000 | 100 |
| Amended Financial Class A | 1,000 | 100 |
| Amended Financial Class (1) | 1,000 | 100 |
| Amended Financial (1) | 1,000 | 100 |
| Dividend on Financial (1) | 1,000 | 100 |
| Dividend on Class A (1) | 1,000 | 100 |
| Dividend on Class A (1) | 1,000 | 100 |

23

T. ROWE PRICE MID-CAP INDEX FUND

| Daily Growth | 5,568 | 100 |
| --- | --- | --- |
| Daily Growth | 5,568 | 100 |
| Daily Growth | 5,568 | 5 Value |
| Daily Growth | 5,568 | 1,000 |
| Daily Growth | 6,000 | 100 |
| Daily Growth | 6,000 | 100 |
| Daily Growth | 6,000 | 100 |
| Daily Growth | 6,000 | 1,000 |
| Daily Growth | 6,000 | 100 |
| Daily Growth | 6,000 | 100 |
| Daily Growth | 6,000 | 100 |
| Daily Growth | 6,000 | 100 |
| Daily Growth | 6,000 | 100 |
| Daily Growth | 6,000 | 100 |

| Daily Growth | 15,000 | 200 |
| --- | --- | --- |
| Daily Growth | 5,000 | 200 |
| Daily Growth | 5,000 | 100 |
| Daily Growth | 5,000 | 100 |
| Daily Growth | 5,000 | 100 |
| ChargePoint Holdings (1)(2) | 6,768 | 65 |

24

T. ROWE PRICE MID-CAP INDEX FUND[{"box_2d": [38, 80, 619, 191], "label": "table", "caption": "

| Airlines 0.4% Class A (1) | 3,788 | 600 |
| --- | --- | --- |
| Airlines Pharmaceutical (1) | 1,500 | 100 |
| Airlines Pharmaceuticals | 5,000 | 5,000 |
| Airlines Pharmaceuticals | 5,000 | 5,000 |
| Airlines Pharmaceuticals | 5,000 | 5,000 |
| Airlines Pharmaceuticals | 5,000 | 5,000 |
| Airlines Pharmaceuticals | 5,000 | 5,000 |
| Airlines Pharmaceuticals | 5,000 | 5,000 |
| Airlines Pharmaceuticals | 5,000 | 5,000 |

| Airlines Pharmaceuticals | 14,960 | 4,900 |
| --- | --- | --- |
| Airlines Pharmaceuticals | 2,400 | 100 |
| Airlines Pharmaceuticals | 2,400 | 100 |
| Airlines Pharmaceuticals | 2,400 | 100 |
| Airlines Pharmaceuticals | 10,400 | 500 |
| Airlines Pharmaceuticals | 10,400 | 500 |
| Airlines Pharmaceuticals | 10,400 | 500 |
| Airlines Pharmaceuticals | 10,400 | 500 |
| Airlines Pharmaceuticals | 10,400 | 500 |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |
| Airlines Pharmaceuticals | 10,400 | 500 |
| Airlines Pharmaceuticals | 10,400 | 500 |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |
| Airlines Pharmaceuticals | 10,400 | 500 |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |
| Airlines Pharmaceuticals | 10,400 | 500 |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |
| Airlines Pharmaceuticals | 10,400 | 500 |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

| Airlines Pharmaceuticals | 10,400 | 500 |
| --- | --- | --- |

<table><tr><td>Airlines Pharmaceuticals</td><td>10,400</td><td>500</td></tr></tabletable><tr><td>Airlines Pharmaceuticals</td><td>10,400</td><td>500</td></tr></tabletable><tr><td>Airlines Pharmaceuticals</td><td>10,400</td><td>500</td></tr></tabletable><tr><td>Airlines Pharmaceuticals</td><td>10,400</td><td>500</td></tr></tabletable><tr><td>Airlines Pharmaceuticals</td><td>10,400</td><td>500</td></tr></tabletable><tr><td>Airlines Pharmaceuticals</td><td>10,400</td><td>500</td></tr></tabletable><tr><td>Airlines Pharmaceuticals</td><td>10,400</td><td>500</td></tr></tabletable><tr><td>Airlines Pharmaceuticals</td><td>10,400</td><td>500</td></tr></tabletable><tr><td>Airlines Pharmaceuticals</td><td>10,400</td><td>500</td></tr></tabletable><tr><td>Airlines Pharmaceuticals</td><td>10,400</td><td>500</td></tr></table

25

T. ROWE PRICE MID-CAP INDEX FUND

| ICU Medical (1) | 547 | 1,500 |
| --- | --- | --- |
| Medical Department (1) | 5,000 | 700 |
| Medical Department (2) | 5,000 | 700 |
| Medical Department (3) | 5,000 | 700 |
| Medical Department (4) | 5,000 | 700 |
| Medical Department (5) | 5,000 | 700 |
| Medical Department (6) | 5,000 | 700 |
| Medical Department (7) | 5,000 | 700 |
| Medical Department (8) | 5,000 | 700 |
| Medical Department (9) | 5,000 | 700 |
| Medical Department (10) | 5,000 | 700 |
| Medical Department (11) | 5,000 | 700 |
| Medical Department (12) | 5,000 | 700 |
| Medical Department (13) | 5,000 | 700 |
| Medical Department (14) | 5,000 | 700 |
| Medical Department (15) | 5,000 | 700 |
| Medical Department (16) | 5,000 | 700 |
| Medical Department (17) | 5,000 | 700 |
| Medical Department (18) | 5,000 | 700 |
| Medical Department (19) | 5,000 | 700 |
| Medical Department (20) | 5,000 | 700 |
| Medical Department (21) | 5,000 | 700 |
| Medical Department (22) | 5,000 | 700 |
| Medical Department (23) | 5,000 | 700 |
| Medical Department (24) | 5,000 | 700 |
| Medical Department (25) | 5,000 | 700 |
| Medical Department (26) | 5,000 | 700 |
| Medical Department (27) | 5,000 | 700 |
| Medical Department (28) | 5,000 | 700 |
| Medical Department (29) | 5,000 | 700 |
| Medical Department (30) | 5,000 | 700 |

26

T. ROWE PRICE MID-CAP INDEX FUND

| Gates Industrial (1) | 3,003 | 34 |
| --- | --- | --- |
| Corporate | 2,998 | 2,998 |
| Total | 3,000 | 3,000 |
| Costs and Liabilities & Supplies (1) | 10,000 | 100 |
| (Cost and value in $000s) | 2,000 | 200 |
| Other (Other) Holdings | 1,000 | 200 |
| Other (Other) Liabilities (1) | 1,000 | 200 |
| Other (Other) Liabilities (1) | 1,000 | 10,000 |
| INDUSTRIALS & BUSINESS SERVICES 15.4% | 1,000 | 100 |
| INDUSTRIALS & BUSINESS SERVICES (1) | 1,000 | 100 |
| INDUSTRIALS & BUSINESS (1) | 1,000 | 100 |
| Net Income (1) | 1,000 | 100 |
| Other (Other) Liabilities (1) | 1,000 | 100 |
| Total (Other) Liabilities, Class A | 1,000 | 100 |

27

T. ROWE PRICE MID-CAP INDEX FUND

| Data/Health Solutions (1) | 2,016 | 2,354 |
| --- | --- | --- |
| Marine Solutions (1) | 2,000 | 2,000 |
| Marine Solutions (1) | 2,000 | 2,000 |
| Construction & Engineering 1.1% | 5,000 | 5,000 |
| Construction & Engineering 1.1% | 5,000 | 5,000 |
| Construction & Engineering Services | 3,000 | 14,000 |
| Construction & Engineering Services | 3,000 | 14,000 |
| Construction & Engineering Services 1.2% | 1,000 | 1,000 |
| Construction & Engineering Services 1.2% | 1,000 | 1,000 |
| Construction & Engineering 0.4% | 1,000 | 1,000 |
| Construction & Engineering Services (1) | 1,000 | 1,000 |
| Construction & Engineering Services (1) | 1,000 | 1,000 |
| Construction & Engineering Services (1) | 1,000 | 1,000 |
| Construction & Engineering Services (1) | 1,000 | 1,000 |
| Construction & Engineering Services (1) | 1,000 | 1,000 |
| Construction & Engineering (1) | 1,000 | 1,000 |
| Chemicals | 4,052 | 124 |

28

T. ROWE PRICE MID-CAP INDEX FUND[{"box_2d": [35, 81, 618, 194], "label": "table", "caption": "

| Information, Class A (1) | 1,995 | 116 |
| --- | --- | --- |
| Department, Holdings | 1,995 | 116 |
| Department, (1) | 1,995 | 116 |
| Department, (1) | 1,995 | 116 |
| Department, (1) | 24,777 | 201 |
| Department, (1) | 1,000 | 101 |
| Department, (1) | 1,000 | 101 |
| Department, (1) | 1,000 | 101 |
| Department, (1) | 1,000 | 101 |
| Department, (1) | 1,000 | 101 |
| Department, (1) | 1,000 | 101 |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |
| Department, (1) | 1,000 | 101 |
| Department, (1) | 1,000 | 101 |
| Department, (1) | 1,000 | 101 |
| Department, (1) | 1,000 | 101 |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |
| Department, (1) | 1,000 | 101 |
| Department, (1) | 1,000 | 101 |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |
| Department, (1) | 1,000 | 101 |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |
| Department, (1) | 1,000 | 101 |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |
| Department, (1) | 1,000 | 101 |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

| Department, (1) | 1,000 | 101 |
| --- | --- | --- |

<table><tr><td>Department, (1)</td><td>1

T. ROWE PRICE MID-CAP INDEX FUND

| Deferred Networks (1) | 3,000 | 1,000 |
| --- | --- | --- |
| Projected Network Group, REIT | 2,000 | 500 |
| Projected Network Group, REIT | 2,000 | 5 Value |
| Projected Network Group, REIT | 2,000 | 1,000 |
| Projected Network Group, REIT | 2,000 | 500 |
| Projected Network Group, REIT | 2,000 | 200 |
| Projected Network Group, REIT | 2,000 | 100 |
| Projected Network Group, REIT | 2,000 | 2,000 |
| Projected Network Group, REIT | 2,000 | 100 |
| Projected Network Group, REIT | 2,000 | 2,000 |
| Projected Network Group, REIT | 2,000 | 100 |
| Projected Network Group, REIT | 2,000 | 2,000 |

30

T. ROWE PRICE MID-CAP INDEX FUND

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |
| AppLovin, Class A (1)(2) | 5,972 | 63 |
| AppLovin, Class A (1)(2) | 5,972 | 63 |
| AppLovin, Class A (1)(2) | 5,972 | 63 |
| AppLovin, Class A (1)(2) | 5,972 | 63 |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |
| AppLovin, Class A (1)(2) | 5,972 | 63 |
| AppLovin, Class A (1)(2) | 5,972 | 63 |
| AppLovin, Class A (1)(2) | 5,972 | 63 |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |
| AppLovin, Class A (1)(2) | 5,972 | 63 |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |
| AppLovin, Class A (1)(2) | 5,972 | 63 |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |
| AppLovin, Class A (1)(2) | 5,972 | 63 |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |
| AppLovin, Class A (1)(2) | 5,972 | 63 |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

| AppLovin, Class A (1)(2) | 5,972 | 63 |
| --- | --- | --- |

</table>

31

T. ROWE PRICE MID-CAP INDEX FUND

| Medical Education Trust (MST) (3) | 15,933 | 10,668 |
| --- | --- | --- |
| Technology Hardware, Storage & Peripherals 0.5% | 4,782 | 219 |
| Medical Education Resources, Reti | 4,782 | 219 |
| Dr. M. M. M. M. M. M. M. Reserve Fund, 4.30% (3)(4) | 1,980,000 | 1,980,000 |
| Dr. M. M. M. M. M. M. M. M. M. M. M. M. M. M. M. M. M. M. M. M. M. M. M. M. M. M. M. M. M. M. M. M. M. M. M. M. M. M. M. M. M. M. M. M. M. M. M. | 4,782 | 219 |
| Medical Education Resources, Reti | 4,782 | 219 |
| Medical Education Resources, Reti | 4,782 | 219 |
| Medical Education Resources, Reti | 4,782 | 219 |
| Medical Education Resources, Reti | 4,782 | 219 |

Medical Education Resources, Reti
Medical Education Resources, Reti
Medical Education Resources, Reti
Medical Education Resources, Reti
Medical Education Resources, Reti
Medical Education Resources, Reti
Medical Education Resources, Reti
Medical Education Resources, Reti
Medical Education Resources, Reti
Medical Education Resources, Reti
Medical Education Resources, Reti
Medical Education Resources, Reti
Medical Education Resources, Reti

32

T. ROWE PRICE MID-CAP INDEX FUND

December 31, 2022

| Securities in a company that is under common ownership or control. The following securities are not included in the Company's business, but are not included in the Company's business, but are not included in the Company's business, but are not included in the Company's business, but are not included in the Company's business, but are not included in the Company's business, but are not included in the Company's business, but are not included in the Company's business, but are not included in the Company's business, but are not included in the Company's business, but are not included in the Company's business | 2,000 | $1,000 |
| --- | --- | --- |
| STORE CAPITAL, BELT | 6,841 | 210 |
| Balance at the end of the year ended December 31, 2022 | 3,274 | 408 |
| STORE TOTAL INVESTMENTS, 0.0% | 1,978 | 414 |
| W.P. LATEY, BELT | 1,978 | 414 |
| Shares are denominated in U.S. dollars unless otherwise noted | 5,634 | 11 |
| Shares at the end of the year ended December 31, 2022 | 5,634 | 11 |
| Money market funds, 0.0% | Change in Net | 5,634 |
| Real Estate, Real Estate, and other non-current assets | Net Realized | Unrealized |
| Real Estate, Real Estate, and other non-current assets | Gain (Loss) | Gain/Loss |
| Amortization of the Company's equity | 994 | 34 |
| Total Assets, 0.0% | $1,285 | 205 |
| Total Assets, 0.0% |  | 46 |
| Jones Lang, Laddell (4) |  |  |
| Receivable for shares sold |  | 14 |
| Other assets |  | 94,005 |
| Total assets |  |  |

33

T. ROWE PRICE MID-CAP INDEX FUND

| STATEMENT OF ASSETS AND LIABILITIES |  | $ | $ | $ | $ |
| --- | --- | --- | --- | --- | --- |
| Group, except shares and par share (in millions) to the shareholder |  |  | 6,145 |  | 9 |
| Support Investment Schedule |  |  | 1,505 |  | 47 |
| Zillow Group Class C (1) | Value | Purchase | Sales | Value |  |
| Affiliate | 12/31/21 | Cost | Cost | 12/31/22 |  |
| T. Rowe Price Government |  |  |  | End of |  |
| Total F |  |  |  | $12/31/22 |  |
| Investment management fees payable |  |  |  | $2,015 |  |
| Payable for shares redeemed |  |  |  | 7 |  |
| Other liabilities (net of foreign taxes of $1) |  |  |  | $1,138 |  |
| Total liabilities lending |  |  |  | 2,379 |  |
| Total income |  |  |  | 1,191 |  |
| Expenses |  |  |  |  |  |

The accompanying notes are an integral part of these financial statements.

34

T. ROWE PRICE MID-CAP INDEX FUND

# STATEMENT OF OPERATIONS

| [B000] |  |  |
| --- | --- | --- |
| # Capital gain distributions from underlying Price funds represented $0 of the net realized gain (loss). |  |  |
| ++ Excludes earnings on securities lending collateral, which are subject to rebates and fees as described in Note 3. |  |  |
|  | Year | $91,826 |
| + Investment management |  |  |
| Investment income comprised $2 of dividend income and $0 of interest income. |  |  |
| n |  |  |
| n |  |  |
| a |  |  |
| The net realized gain in net assets (loss) of the net realized gain (loss) of $0.0001 par value, except at the outstanding: 2,000,000,000 shares of the net realized gain (loss) |  |  |
|  | 1,074 | $600 |
| Commodity and related (loss) |  |  |
|  | (4,253) | 1,247 |
| Commodity and related gain / loss |  |  |
|  | (27,806) | 1,914 |
| NET ASSETS (Increase) in net assets from operations |  |  |
|  | (30,984) | $91,826 |

The accompanying notes are an integral part of these financial statements.

35

## Ex-99.Cert

**Item 13. (a)(2)** 

**<u>CERTIFICATIONS</u>**

I, David Oestreicher, certify that:

1. I have reviewed this report on Form N-CSR of T. Rowe Price Mid-Cap
Index Fund;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state
a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations, changes in net assets, and cash flows (if the financial statements are required to include a statement of cash flows) of the registrant as of, and for, the
periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in
this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that
occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed to the registrant's auditors and
the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role
in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: February 21, 2023 | /s/ David Oestreicher |
|  | David Oestreicher |
|  | Principal Executive Officer |

---

------

**<u>CERTIFICATIONS</u>**

I, Alan S. Dupski, certify that:

1. I have reviewed this report on Form N-CSR of T. Rowe Price Mid-Cap Index Fund;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state
a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations, changes in net assets, and cash flows (if the financial statements are required to include a statement of cash flows) of the registrant as of, and for, the
periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in
this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that
occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed to the registrant's auditors and
the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role
in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: February 21, 2023 | /s/ Alan S. Dupski |
|  | Alan S. Dupski |
|  | Principal Financial Officer |

---

## Exhibit 99.906

**Item 13. (b)** 

**CERTIFICATION UNDER SECTION 906 OF SARBANES-OXLEY ACT OF 2002** 

Name of Issuer: T. Rowe Price Mid-Cap Index Fund

In connection with the Report on Form N-CSR for the above named Issuer, the undersigned hereby certifies, to the best of his knowledge, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange
Act of 1934;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The information contained in the Report fairly presents, in all material respects, the financial condition
and results of operations of the Issuer.

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Date: February 21, 2023 | /s/ David Oestreicher |
|  | David Oestreicher |
|  | Principal Executive Officer |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Date: February 21, 2023 | /s/ Alan S. Dupski |
|  | Alan S. Dupski |
|  | Principal Financial Officer |

---

## Ex-99.Code

**CODE OF ETHICS FOR PRINCIPAL EXECUTIVE AND SENIOR FINANCIAL** 

**OFFICERS OF THE T. ROWE PRICE MUTUAL FUNDS AND EXCHANGE-** 

**TRADED FUNDS** 

**UNDER THE SARBANES-OXLEY ACT OF 2002** 

**I. General Statement.** This Code of Ethics for the T. Rowe Price Mutual Funds and Exchange-Traded Funds (the "Price ETFs" and, together with the Mutual Funds, the **"Price Funds")** has been designed to bring the Price Funds into compliance with the applicable requirements of the Sarbanes-Oxley Act of 2002 (the **"Act")** and rules promulgated by the Securities and Exchange Commission thereunder ("Regulations"). This Price Funds' Code of Ethics (the **"S-O Code")** applies solely to the Principal Executive Officer, Principal Financial Officer, Principal Accounting Officer or Controller of, or persons performing similar functions for, a Price Fund (whether such persons are employed by a Price Fund or third party) **("Covered Officers").** The **"Price Funds"** shall include each mutual fund and ETF that is managed, sponsored and distributed by affiliates of T. Rowe Price Group, Inc. **("Group").** The investment managers to the Price Funds will be referred to as the **"Price Fund Advisers."** A list of Covered Officers is attached as **Exhibit A.**

The Price Fund Advisers have, along with their parent, T. Rowe Price Group, Inc. **("Group")** also maintained a comprehensive Code of Ethics and Conduct (the **"Group Code")** since 1972, which applies to all officers, directors and employees of the Price Funds, Group and its affiliates.

As mandated by the Act, Group has adopted a Code (the **"Group S-O Code"),** similar to the Price Funds S-O Code, which applies solely to its principal executive and senior financial officers. The Group S-O Code and the Price Funds S-O Code will be referred to collectively as the **"S-O Codes".**

The Price Funds S-O Code has been adopted by the Price Funds in accordance with the Act and Regulations thereunder and will be administered in conformity with the disclosure requirements of Item 2 of Form N-CSR. The S-O Codes are attachments to the Group Code. In many respects the S-O Codes are supplementary to the Group Code, but the Group Code is administered separately from the S-O Codes, as the S-O Codes are from each other.

**II. Purpose of the Price Funds S-O Code.** The purpose of the Price Funds S-O Code, as mandated by the Act and the Regulations, is to establish standards that are reasonably designed to deter wrongdoing and to promote:

**Ethical Conduct.** Honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships.

**Disclosure.** Full, fair, accurate, timely and understandable disclosure in reports and documents that the Price Funds file with, or submit to, the SEC and in other public communications made by the Price Funds.

**Compliance.** Compliance with applicable governmental laws, rules and regulations.

**Reporting of Violations.** The prompt internal reporting of violations of the Price Funds S-O Code to an appropriate person or persons identified in the Price Funds S-O Code.

**Accountability.** Accountability for adherence to the Price Funds S-O Code.

------

**III. Covered Officers Should Handle Ethically Actual and Apparent Conflicts of Interest.** 

**Overview.** Each Covered Officer owes a duty to the Price Funds to adhere to a high standard of honesty and business ethics and should be sensitive to situations that may give rise to actual as well as apparent conflicts of interest.

A "conflict of interest" occurs when a Covered Officer's private interest interferes with the interests of, or his or her service to, the Price Funds. For example, a conflict of interest would arise if a Covered Officer, or a member of his or her family, receives improper personal benefits as a result of his or her position with a Price Fund.

Certain conflicts of interest covered by the Price Funds S-O Code arise out of the relationships between Covered Officers and the Price Funds and may already be subject to provisions regulating conflicts of interest in the Investment Company Act of 1940 **("Investment Company Act"),** the Investment Advisers Act of 1940 **("Investment Advisers Act")** and the Group Code. For example, Covered Officers may not individually engage in certain transactions (such as the purchase or sale of securities or other property) with a Price Fund because of their status as "affiliated persons" of a Price Fund. The compliance programs and procedures of the Price Funds and Price Fund Advisers are designed to prevent, or identify and correct, violations of these provisions.

Although typically not presenting an opportunity for improper personal benefit, conflicts arise from, or as a result of, the contractual relationship between a Price Fund and its Price Fund Adviser (and its affiliates) of which the Covered Officers may also be officers or employees. As a result, the Price Funds S-O Code recognizes that the Covered Officers will, in the normal course of their duties (whether formally for the Price Funds or for the Price Fund Advisers, or for both), be involved in establishing policies and implementing decisions which will have different effects on these entities. The participation of the Covered Officers in such activities is inherent in the contractual relationship between each Price Fund and its respective Price Fund Adviser. Such participation is also consistent with the performance by the Covered Officers of their duties as officers of the Price Funds and, if consistent with the provisions of the Investment Company Act and the Investment Advisers Act, it will be deemed to have been handled ethically.

Other conflicts of interest are covered by the Price Funds and Price ETFs S-O Code, even if these conflicts of interest are not addressed by or subject to provisions in the Investment Company Act and the Investment Advisers Act.

Whenever a Covered Officer is confronted with a conflict of interest situation where he or she is uncertain as to the appropriate action to be taken, he or she should discuss the matter with the Chairperson of Group's Ethics Committee or another member of the Committee.

**Handling of Specific Types of Conflicts.** Each Covered Officer (and close family members) must not:

**Entertainment.** Accept entertainment from any company with which any Price Fund or any Price Fund Adviser has current or prospective business dealings including portfolio companies, unless such entertainment is in full compliance with the policy on entertainment as set forth in the Group Code.

------

**Gifts.** Accept any gifts, except as permitted by the Group Code.

**Improper Personal Influence.** Use his or her personal influence or personal relationships improperly to influence investment decisions, brokerage allocations or financial reporting by the Price Funds to the detriment of any one or more of the Price Funds.

**Taking Action at the Expense of a Price Fund.** Cause a Price Fund to take action, or fail to take action, for the personal benefit of the Covered Officer rather than for the benefit of one or more of the Price Funds.

**Misuse of Price Funds' Transaction Information.** Use knowledge of portfolio transactions made or contemplated for a Price Fund or any other clients of the Price Fund Advisers to trade personally or cause others to trade in order to take advantage of or avoid the market impact of such portfolio transactions; and in connection with Price ETFs that do not disclose portfolio holdings daily, use knowledge of pending changes to an ETF's proxy portfolio holdings for such purposes.

**Outside Business Activities.** Engage in any outside business activity that detracts from a Covered Officer's ability to devote appropriate time and attention to his or her responsibilities to a Price Fund.

**Service Providers.** Excluding Group and its affiliates, have any ownership interest in, or any consulting or employment relationship with, any of the Price Funds' service providers, except that an ownership interest in public companies is permitted

**Receipt of Payments.** Have a direct or indirect financial interest in commissions, transaction charges, spreads or other payments paid by a Price Fund for effecting portfolio transactions or for selling or redeeming shares other than an interest (such as compensation or equity ownership) arising from the Covered Officer's employment by Group or any of its affiliates.

**Service as a Director or Trustee.** Serve as a director, trustee or officer of any public or private company or a non-profit organization that issues securities eligible for purchase by any of the Price Funds, unless approval is obtained as required by the Group Code.

**IV. Covered Officers' Specific Obligations and Accountabilities.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**A. Disclosure Requirements and Controls.** Each Covered Officer must familiarize himself or herself with the disclosure requirements (Form N-lA registration statement, proxy (Schedule 14A), shareholder reports, Forms N-CEN, N-CSR, etc.) applicable to the Price Funds and the disclosure controls and procedures of the Price Fund and the Price Fund Advisers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**B. Compliance with Applicable Law.** It is the responsibility of each Covered Officer to promote compliance with all laws, rules and regulations applicable to the Price Funds and the Price Fund Advisers. Each Covered Officer should, to the extent appropriate within his or her area of responsibility, consult with other officers and employees of the Price Funds and the Price Fund Advisers and take other appropriate steps with the goal of promoting full, fair, accurate, timely and understandable disclosure in the reports and documents the Price Funds file with, or submit to, the SEC, and in other public

------

communications made by the Price Funds.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**C. Fair Disclosure.** Each Covered Officer must not knowingly misrepresent, or cause others to misrepresent, facts about a Price Fund to others, whether within or outside the Price organization, including to the Price Fund's directors and auditors, and to governmental regulators and self-regulatory organizations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**D. Initial and Annual Affirmations.** Each Covered Officer must:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Upon adoption of the Price Funds S-O Code (or thereafter, as applicable, upon becoming a Covered Officer), affirm in writing that he or she has received, read, and understands the Price Funds S-O Code.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Annually affirm that he or she has complied with the requirements of the Price Funds S-O Code.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**E. Reporting of Material Violations of the Price Funds S-O Code.** If a Covered Officer becomes aware of any material violation of the Price Funds S-O Code or laws and governmental rules and regulations applicable to the operations of the Price Funds, he or she must promptly report the violation **("Report")** to the Chief Compliance Officer of the Price Funds **("CCO").** Failure to report a material violation will be considered itself a violation of the Price Funds S-O Code. The CCO is identified in the attached **Exhibit B.**

It is the Price Funds' policy that no retaliation or other adverse action will be taken against any Covered Officer or other employee of a Price Fund, a Price Fund Adviser or their affiliates based upon any lawful actions of the Covered Officer or employee with respect to a Report made in good faith.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**F. Annual Disclosures.** Each Covered Officer must report, at least annually, all affiliations or other relationships as called for in the "Annual Compliance Certification" for T. Rowe Price Group.

**V. Administration of the Price Funds S-O Code.** The Ethics Committee is responsible for administering the Price Funds S-O Code and applying its provisions to specific situations in which questions are presented.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**A. Waivers and Interpretations.** The Chairperson of the Ethics Committee has the authority to interpret the Price Funds S-O Code in any particular situation and to grant waivers where justified, subject to the approval of the Joint Audit Committee of the Price Funds. All material interpretations concerning Covered Officers will be reported to the Joint Audit Committee of the Price Funds at its next meeting. Waivers, including implicit waivers, to Covered Officers will be publicly disclosed as required in the Instructions to N-CSR. Pursuant to the definition in the Regulations, an implicit waiver means a Price Fund's failure to take action within a reasonable period of time regarding a material departure from a provision of the Price Funds S-O Code that has been made known to an "executive officer" (as defined in Rule 3b-7 under the Securities Exchange Act of 1934) of a Price Fund. An executive officer of a Price Fund includes its president and any vice-president in charge of a principal business unit, division or function.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**B. Violations/Investigations.** The following procedures will be followed in

------

investigating and enforcing the Price Funds S-O Code:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The CCO will take or cause to be taken appropriate action to investigate any potential or actual violation reported to him or her.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The CCO, after consultation if deemed appropriate with Outside Counsel to the Price Funds, will make a recommendation to the appropriate Price Funds Board regarding the action to be taken with regard to each material violation. Such action could include any of the following: a letter of censure or suspension, a fine, a suspension of trading privileges or termination of officership or employment. In addition, the violator may be required to surrender any profit realized (or loss avoided) from any activity that is in violation of the Price Funds S-O Code.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Investigations of Whistleblower complaints related to Price Funds will be handled in accordance with the T. Rowe Price Global Whistleblower Policy.

**VI. Amendments to the Price Funds S-O Code.** Except as to the contents of **Exhibit A and Exhibit B,** the Price Funds S-O Code may not be materially amended except in written form, which is specifically approved or ratified by a majority vote of each Price Fund Board, including a majority of the independent directors on each Board.

**VII. Confidentiality.** All reports and records prepared or maintained pursuant to the Price Funds S-O Code will be considered confidential and shall be maintained and protected accordingly. Except as otherwise required by law, the Price Funds S-O Code or as necessary in connection with regulations under the Price Funds S-O Code, such matters shall not be disclosed to anyone other than the directors of the appropriate Price Fund Board, Outside Counsel to the Price Funds, members of the Ethics Committee and the CCO and authorized persons on his or her staff.

Adoption Date: 10/22/03

Last Revised: 05/11/2022 (Exhibit B revised)

------

## Exhibit A
**Persons Covered by the Price Funds and** 

**Price ETFs S-O Code of Ethics** 

David Oestreicher, Executive Vice President and Principal Executive Officer

Alan S. Dupski, Treasurer and Principal Financial Officer

## Exhibit B
Dino Capasso, Chief Compliance Officer